Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Retrovirology Research cung cấp cho các bạn kiến thức về ngành y đề tài:"The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. | Retrovirology BioMed Central Research The triple combination of tenofovir emtricitabine and efavirenz shows synergistic anti-HIV-l activity in vitro a mechanism of action study Joy Y Feng John K Ly Florence Myrick Derrick Goodman Kirsten L White Evguenia S Svarovskaia Katyna Borroto-Esoda and Michael D Miller Open Access Address Gilead Sciences Inc 333 Lakeside Drive Foster City California 94404 USA Email Joy Y Feng John K Florence Derrick Goodman - Kirsten LWhite - Evguenia S Svarovskaia - Katyna Borroto-Esoda - Michael D Miller - Corresponding author Published 13 May 2009 Received 15 January 2009 Retrovirology 2009 6 44 doi 1742-4690-6-44 Accepted 13 May 2009 This article is available from http content 6 1 44 2009 Feng et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Tenofovir disoproxil fumarate TDF emtricitabine FTC and efavirenz EFV are the three components of the once-daily single tablet regimen Atripla for treatment of HIV-1 infection. Previous cell culture studies have demonstrated that the double combination of tenofovir TFV the parent drug of TDF and FTC were additive to synergistic in their anti-HIV activity which correlated with increased levels of intracellular phosphorylation of both compounds. Results In this study we demonstrated the combinations of TFV FTC TFV EFV FTC EFV and TFV FTC EFV synergistically inhibit HIV replication in cell culture and synergistically inhibit HIV-1 reverse transcriptase RT catalyzed DNA synthesis in biochemical
